Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1982 1
1983 1
1984 2
1985 2
1986 2
1987 1
1988 1
1995 1
1996 2
1997 1
1998 2
2000 1
2001 1
2002 1
2003 1
2004 2
2006 4
2008 5
2009 4
2010 10
2011 8
2012 5
2013 2
2014 5
2015 2
2016 2
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Results by year
Filters applied: . Clear all
Page 1
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Davidson M, et al. Cardiovasc Drugs Ther. 2012 Aug;26(4):349-58. doi: 10.1007/s10557-012-6395-z. Cardiovasc Drugs Ther. 2012. PMID: 22622962 Free PMC article. Clinical Trial.
PURPOSE: Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of once-daily fenofibric
PURPOSE: Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk a …
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR, Digiacinto J, Davis MW. Godfrey AR, et al. Clin Ther. 2011 Jun;33(6):766-75. doi: 10.1016/j.clinthera.2011.05.047. Clin Ther. 2011. PMID: 21704241 Clinical Trial.
Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate. ...Fenofibric acid at the dose stu …
Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally adminis …
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Jones PH, et al. Clin Drug Investig. 2008;28(10):625-34. doi: 10.2165/00044011-200828100-00003. Clin Drug Investig. 2008. PMID: 18783301 Clinical Trial.
A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid. METHODS: Three separate 22-week, phase III, double-blind, active-controlled trials will evalu …
A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new …
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, Leal SM, Ballantyne CM. Brautbar A, et al. Atherosclerosis. 2011 Dec;219(2):737-42. doi: 10.1016/j.atherosclerosis.2011.08.015. Epub 2011 Aug 22. Atherosclerosis. 2011. PMID: 21889769 Free PMC article. Clinical Trial.
We sought to identify single nucleotide polymorphisms (SNPs) associated with HDL-C, TG, and apolipoprotein A1 (ApoA-I) response to combination therapy with statins and fenofibric acid (FA) in individuals with atherogenic dyslipidemia. METHODS: 2228 individuals with …
We sought to identify single nucleotide polymorphisms (SNPs) associated with HDL-C, TG, and apolipoprotein A1 (ApoA-I) response to combinati …
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD, Dane AL, Schneck DW, Warwick MJ. Martin PD, et al. Clin Ther. 2003 Feb;25(2):459-71. doi: 10.1016/s0149-2918(03)80089-9. Clin Ther. 2003. PMID: 12749507 Clinical Trial.
OBJECTIVE: The effect of coadministration of rosuvastatin and fenofibrate on the steady-state pharmacokinetics of rosuvastatin and fenofibric acid (the active metabolite of fenofibrate) was assessed in healthy volunteers. ...CONCLUSION: Coadministration of rosuvasta …
OBJECTIVE: The effect of coadministration of rosuvastatin and fenofibrate on the steady-state pharmacokinetics of rosuvastatin and fenofi
Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. Zhu T, et al. J Clin Pharmacol. 2010 Aug;50(8):914-21. doi: 10.1177/0091270009354995. Epub 2010 Feb 9. J Clin Pharmacol. 2010. PMID: 20145261 Clinical Trial.
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and fenofibrate (which is converted to fenofibric acid in vivo) in healthy volunteers. ...Serial blood samples were collected for 1 …
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and f …
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM. Brautbar A, et al. J Lipid Res. 2012 Mar;53(3):556-560. doi: 10.1194/jlr.M020404. Epub 2012 Jan 11. J Lipid Res. 2012. PMID: 22236405 Free PMC article. Clinical Trial.
We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and fenofibric acid (FA) in individuals with mixed dyslipidemia. Participants (n = 1,250) in a multicenter, randomized, double-bl …
We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and …
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH. Roth EM, et al. Am J Cardiovasc Drugs. 2010;10(3):175-86. doi: 10.2165/11533430-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20524719 Clinical Trial.
Primary and secondary variables were mean percent changes in LDL-C comparing rosuvastatin/fenofibric acid 20 mg/135 mg with simvastatin 40 mg and rosuvastatin/fenofibric acid 10 mg/135 mg and rosuvastatin/fenofibric acid 5 mg/135 mg with …
Primary and secondary variables were mean percent changes in LDL-C comparing rosuvastatin/fenofibric acid 20 mg/135 mg with si …
Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
Gordon LA, Malati CY, Hadigan C, McLaughlin M, Alfaro RM, Calderón MM, Kovacs JA, Penzak SR. Gordon LA, et al. Pharmacotherapy. 2016 Jan;36(1):49-56. doi: 10.1002/phar.1682. Pharmacotherapy. 2016. PMID: 26799348 Free PMC article. Clinical Trial.
MEASUREMENTS AND MAIN RESULTS: Serial blood samples were collected over 120 hours for determination of fenofibric acid concentrations. Fenofibric acid pharmacokinetic parameter values were compared before and after concomitant ritonavir or lopinavir-ri …
MEASUREMENTS AND MAIN RESULTS: Serial blood samples were collected over 120 hours for determination of fenofibric acid concent …
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC. Kipnes MS, et al. Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000. Clin Drug Investig. 2010. PMID: 19995098 Clinical Trial.
The incidence of discontinuation due to adverse events was 2.9% overall. Rhabdomyolysis was not reported in any group. Overall, fenofibric acid + moderate-dose statin for > or =2 years resulted in sustained improvements in HDL-C (+17.4%), TG (-46.4%) and LDL-C (- …
The incidence of discontinuation due to adverse events was 2.9% overall. Rhabdomyolysis was not reported in any group. Overall, fenofibri
68 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page